Search
News
Novavax Q2 2026 earnings: Revenue falls as prior-year payments roll off
Novavax’s Q2 2026 revenue fell 76% year over year to $56.7 million as prior-year milestone and amendment revenue rolled off, while diluted EPS shifted to a $0.32 loss from $0.62 profit. Product sales rose 76% to $18.9 million, but licensing, royalties and other revenue dropped 83% to $37.8 million. The company raised its full-year adjusted revenue framework to $235 million-$275 million and reduced GAAP combined R&D and SG&A guidance to $370 million-$410 million, while leaving the non-GAAP expense range unchanged. Cash and related holdings ended June at $723.9 million.
TradingKey
Thu, Aug 6
Koppers Q2 2026 Earnings: Sales Rise as Margins Weaken
Koppers’ Q2 2026 earnings showed a 3.0% increase in net sales to $520.1 million, but adjusted EBITDA fell 7.9% to $71.0 million as raw-material, freight, and legal costs, unfavorable RUPS pricing, and divestitures pressured profitability. A $215.8 million impairment, restructuring, and plant-closure charge drove a GAAP net loss of $147.5 million and diluted EPS of negative $7.71. Performance Chemicals improved while RUPS and Carbon Materials and Chemicals weakened, prompting Koppers to narrow adjusted EBITDA and adjusted EPS guidance while maintaining its cash-flow outlook.
TradingKey
Thu, Aug 6
MACOM Fiscal Q3 2026 Earnings: Revenue Growth Expanded Operating Margins
MACOM Technology Solutions (MTSI) reported fiscal third-quarter 2026 revenue of $342.2 million, up 35.8% year over year, while GAAP diluted EPS rose to $1.28 from $0.48. GAAP operating margin expanded to 22.5% from 14.9%, reflecting higher gross margin and operating leverage, though a $41.5 million investment fair-value gain materially lifted net income. For fiscal Q4, MACOM guided to $415 million-$425 million in revenue, a 60.0%-61.0% adjusted gross margin, and adjusted EPS of $1.97-$2.03, requiring a sizable sequential revenue step-up.
TradingKey
Thu, Aug 6
Lexicon Q2 2026 earnings: Revenue drops without prior-year license income
Lexicon Pharmaceuticals’ (LXRX) Q2 2026 revenue fell about 97.6% to $0.7 million from $28.9 million, largely because the year-earlier period included $27.5 million of Novo Nordisk licensing revenue. Diluted EPS swung to a $0.07 loss from $0.01 of income, and the company posted a $31.8 million net loss. Cash, investments and restricted cash rose to $190.6 million after a $96.2 million equity raise, while SONATA-HCM enrollment was completed. The quarter also included a $4.3 million loss on early debt extinguishment.
TradingKey
Thu, Aug 6
Genie Energy Q2 2026 Earnings: Margin Expansion Lifts EPS Despite Lower Revenue
Genie Energy’s (NYSE: GNE) Q2 2026 revenue fell 4.6% year over year to $100.4 million, but gross margin expanded to 33.5% from 22.3% as retail energy market conditions normalized. Diluted EPS rose to $0.43 from $0.09, and adjusted EBITDA increased to $7.5 million from $3.0 million. GRE produced the main operating improvement, while GREW moved to positive adjusted EBITDA. The company maintained full-year adjusted EBITDA guidance of $32.5 million to $40 million, though first-half operating cash flow remained negative amid working-capital outflows.TradingKey
Thu, Aug 6
Kelly Q2 2026 earnings: Underlying revenue decline narrows to 0.6%
Kelly Services’ fiscal Q2 2026 revenue fell 5.8% to $1.04 billion, but the underlying decline narrowed to about 0.6% after excluding disclosed federal-contractor and large-customer effects. Diluted EPS decreased to $0.31 from $0.52, while adjusted EBITDA was $31.1 million and its margin recovered sequentially to 3.0%, though it remained 40 basis points below last year. ETM and SET showed improving demand trends, and Kelly raised its full-year revenue outlook to a low-to-mid-single-digit decline while retaining expectations for adjusted EBITDA margin expansion.TradingKey
Thu, Aug 6
Collegium Q2 2026 Earnings: Acquisition Costs Push GAAP Results Into a Loss
Collegium Pharmaceutical's Q2 2026 net revenue rose 6% year over year to $199.9 million, while GAAP diluted EPS swung to a $0.46 loss from $0.34 in earnings. JORNAY PM revenue increased 41% to $46.1 million and AZSTARYS contributed $12.9 million for a partial quarter, but the pain portfolio declined 9%. Adjusted EBITDA grew 8% to $113.8 million. The company lowered full-year net product revenue and adjusted EBITDA guidance, largely because authorized-generic Nucynta net pricing was below expectations, despite raising its AZSTARYS revenue outlook.
TradingKey
Thu, Aug 6
Parker Fiscal Q4 2026 Earnings: Organic Growth Broadens as Margins Rise
Parker Hannifin’s fiscal Q4 2026 revenue rose 9.8% to $5.755 billion, with organic sales up 8.0%, while diluted EPS increased 19% to $8.54. Adjusted segment operating margin expanded 110 basis points to 28.0%, supported by double-digit Aerospace Systems growth and improving industrial demand. Aerospace sales climbed 13.4%, and total backlog reached $12.8 billion. Adjusted EPS reached a record $9.27. Parker’s fiscal 2027 guidance calls for 5.5% to 8.5% reported and organic sales growth, excluding two pending acquisitions.
TradingKey
Thu, Aug 6
Compass Therapeutics Q2 2026 earnings: Pipeline spending widens the net loss
Compass Therapeutics’ Q2 2026 earnings showed a net loss of $25.2 million, compared with $19.9 million a year earlier, while basic and diluted loss per share narrowed to $0.13 from $0.14 as the weighted-average share count increased. R&D expense rose 19% to $19.6 million, largely due to tovecimig, and G&A expense increased 59% to $7.4 million. The company ended June with $180 million in cash and marketable securities, expects runway into 2028, and is awaiting Q3 FDA feedback before a potential tovecimig BLA filing later in 2026.
TradingKey
Thu, Aug 6
InflaRx Q2 2026 earnings: Lower costs narrow the operating loss
InflaRx (IFRX) reported Q2 2026 revenue of €0 and a basic and diluted loss of €0.09 per share, improving from €0.21 a year earlier. The operating loss narrowed to €7.1 million from €12.9 million as R&D, G&A and sales expenses declined, while the net loss improved to €10.6 million. Following a May equity offering, cash, cash equivalents and marketable securities reached €158.4 million at June 30, supporting a projected runway through 2029. The company continued planning izicopan studies in AAV and renal diseases, with initial renal proof-of-concept data targeted for 2027.
TradingKey
Thu, Aug 6
SAB BIO Q2 2026 Results: Clinical Spending Widens Net Loss
SAB BIO’s Q2 2026 net loss widened to $22.5 million from $10.1 million as R&D expense rose to $16.2 million and G&A expense reached $7.2 million. The clinical-stage biotech ended June with $208.0 million in cash, cash equivalents and investment securities, providing a stated operating runway through 2028. More than 60 SAFEGUARD sites were activated, enrollment remained targeted for completion in Q4 2026, and topline SAB-142 data are expected in the second half of 2027. The grant-supported PRISE-hATG study could broaden the program to patients diagnosed up to two years earlier.TradingKey
Thu, Aug 6
Priority Commerce Q2 2026 Earnings: Revenue Grows as GAAP Profit Declines
Priority Commerce reported Q2 2026 revenue of $262.3 million, up 9.4% year over year, while diluted EPS fell 14.3% to $0.12. Adjusted EBITDA increased 6.0% to $59.4 million, but gross margin narrowed by nearly 50 basis points and operating income declined as depreciation, amortization and SG&A rose. Payables and Treasury Solutions delivered double-digit revenue growth, although Payables adjusted EBITDA fell. The company reaffirmed its full-year 2026 guidance as GAAP and adjusted earnings moved in different directions.
TradingKey
Thu, Aug 6
EuroDry Q2 2026 Earnings: Higher Charter Rates Restore Profitability
EuroDry’s Q2 2026 net revenue rose 57.0% to $17.7 million, while diluted EPS reached $2.32 versus a $1.12 loss a year earlier. Adjusted EBITDA increased to $11.7 million from $1.9 million as the average TCE rate nearly doubled to $20,398 per day, more than offsetting a smaller 11-vessel average fleet. The quarter also benefited from a $1.5 million bunker-related voyage gain and lower vessel operating costs. Investors should watch near-term charter renewals, $22.0 million of scheduled debt repayments, and whether drybulk rates remain elevated.
TradingKey
Thu, Aug 6
Ingles Markets Fiscal Q3 2026 Earnings: Sales Rise as Operating Profit Falls
Ingles Markets (NASDAQ: IMKTA) reported fiscal Q3 2026 net sales of $1.368 billion, up about 1.6% year over year, while diluted Class A EPS fell to $1.36 from $1.38. Gross margin held at 24.3%, but operating and administrative expenses rose 2.7%, pushing operating income down 7.7% to $34.5 million. Net income edged lower to $25.9 million. Cash reached $455.1 million, total debt was $500.5 million, and the grocer expects fiscal 2026 capital expenditures of approximately $120 million to $130 million.
TradingKey
Thu, Aug 6
NETSCOUT Q1 FY2027 earnings: Revenue growth restores GAAP profitability
NETSCOUT’s fiscal Q1 2027 revenue rose 12.7% to $210.4 million, while GAAP diluted EPS improved to $0.29 from a $0.05 loss. GAAP operating margin reached 6.9%, versus negative 3.5%, and adjusted EBITDA increased to $46.9 million. Service Assurance, government-related orders received partly ahead of schedule, and newer Omnis products supported the quarter, while Cybersecurity revenue was flat year over year. NETSCOUT reaffirmed FY2027 revenue guidance of $885 million to $915 million and non-GAAP EPS guidance of $2.65 to $2.80.
TradingKey
Thu, Aug 6
ITT Q2 2026 earnings: SPX FLOW drives growth but weighs on GAAP margin
ITT’s Q2 2026 revenue rose 51.5% to $1.47 billion, including 12.7% organic growth, as SPX FLOW and gains in aerospace, defense, connectors and pump projects expanded the top line. Adjusted EPS increased 18.2% to $2.08, but GAAP EPS fell 37.5% to $0.95 as acquisition-related amortization and costs weighed on reported profit. Adjusted operating margin improved 40 basis points to 20.0%, quarterly free cash flow reached $162 million, and ITT raised its 2026 revenue, margin, EPS and cash guidance.
TradingKey
Thu, Aug 6
DSG Q2 2026 Earnings: Organic Growth Lifted Revenue While Margins Narrowed
Distribution Solutions Group (DSG) reported Q2 2026 revenue of $557.7 million, up 11.0% year over year, while diluted EPS rose to $0.18 from $0.11. Organic sales grew 10.2%, but gross margin fell 160 basis points to 32.3% as customer and vertical mix shifted and higher inbound tariff rates offset part of the pricing benefit. Adjusted EBITDA increased 11.1% to $53.9 million with margin unchanged at 9.7%. Quarterly operating cash flow recovered to $22.0 million, and DSG also detailed its pending $35-per-share merger with LKCM Headwater.
TradingKey
Thu, Aug 6
Cheniere Partners Q2 2026 Earnings: Higher LNG Volumes Lift Adjusted EBITDA
Cheniere Energy Partners (NYSE: CQP) reported Q2 2026 revenue of $2.583 billion, up 5% year over year, while net income more than doubled to $1.161 billion and basic and diluted net income per common unit rose to $2.14. Adjusted EBITDA increased 35% to $983 million as recognized LNG volumes climbed 13% to 396 TBtu. Favorable commodity-derivative fair-value changes also amplified GAAP profit growth. The partnership reconfirmed full-year 2026 distribution guidance of $3.10 to $3.40 per common unit and advanced early work on the Sabine Pass expansion.TradingKey
Thu, Aug 6
IBP Q2 2026 Earnings: Revenue Grew as Margins Contracted
Installed Building Products (IBP) reported second-quarter 2026 net revenue of $777.8 million, up 2.3% year over year, while diluted EPS fell to $2.43 from $2.52. Adjusted EBITDA declined 2.3% to $130.9 million and its margin narrowed to 16.9%. Commercial installation and manufacturing and distribution growth offset weaker residential activity, but the shift toward lower-margin Other revenue, higher fuel costs, and medical insurance expense pressured profitability. Cash reached $394.5 million at June 30, although six-month operating cash flow declined and long-term debt increased.
TradingKey
Thu, Aug 6
Cheniere Q2 2026 earnings: LNG volumes lift adjusted EBITDA and guidance
Cheniere Energy’s (NYSE: LNG) second-quarter 2026 revenue rose 24% to $5.732 billion, and diluted EPS increased to $14.65 from $7.30. Consolidated adjusted EBITDA advanced 27% to $1.804 billion as higher LNG volumes and stronger margins per MMBtu supported results. GAAP net income attributable to Cheniere reached $3.068 billion, but favorable derivative fair-value changes amplified reported profit. The company raised full-year adjusted EBITDA guidance to $7.90-$8.40 billion and distributable cash flow guidance to $5.30-$5.80 billion.TradingKey
Thu, Aug 6
Featured Tools
Top News
Meta Q3 Net Profit Surges 264% YoY, Raises Full-Year Capex Slightly; Shares Briefly Rise Over 4% After Hours
US Stocks Close: Nasdaq Gains Over 1%, Philadelphia Semiconductor Index Rises Nearly 2%; Tech Stocks Strengthen, SpaceX Gains Nearly 8% Post-Earnings
US Stocks Close: Nasdaq Drops 2.6%, SOX Falls Over 6%; Jensen Huang's Remarks on Capital Shortage Spark Financing Concerns, Meta Drops 7% After Earnings
Memory Stocks Fall Over 4% as Micron Drops Below $900, Risking Another 16% Fall to Retest Lows
Tesla Q3 Operating Profit Plunges 56% YoY, Dragged Down by Higher Operating Expenses Including R&D
